Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA

Orphan drug designation (ODD) for “treatment of stage IIb-IV melanoma” by FDA

As of May 1, 2020, NewG Lab Pharma received a letter from the FDA for Orphan drug designation (ODD)  for “treatment of stage IIb-IV melanoma”.

As a result, NewG Lab Pharma acquired Orphan drug status for  liver cancer, intra-hepatic bile duct cancer and melanoma.

NewG Lab Pharma plans to start the FDA Phase 1 clinical trial in 2021.